Small molecule FLT3 tyrosine kinase inhibitors

Current Pharmaceutical Design

Volumn 10, Issue 11, 2004, Pages 1183-1193

  Levis, Mark ^a   Small, Donald ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

AML; FLT3; Kinase inhibitor; Tyrosine kinase

Indexed keywords

1 PHENYL 3 H 8 OXA 2,3 DIAZACYCLOPENTA[A]INDEN; 4 [6 METHOXY 7 [3 (1 PIPERIDINYL)PROPOXY] 4 QUINAZOLINYL] 1 PIPERAZINECARBOXYLIC ACID (4 ISOPROPOXYPHENYL)AMIDE; 6,7 DIMETHOXY 2 PHENYLQUINOXALINE; AGL 2033; AMI 10706; CARBAZOLE DERIVATIVE; CEP 701; D 64406; FLT3 LIGAND; GTP 14564; IMATINIB; INDENE DERIVATIVE; MIDOSTAURIN; OXINDOLE; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; QUINAZOLINE DERIVATIVE; QUINOXALINE DERIVATIVE; SEMAXANIB; SUNITINIB; THRX 165724; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; AUTOPHOSPHORYLATION; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; CYTOTOXICITY TEST; DENSITOMETRY; DRUG BLOOD LEVEL; DRUG STRUCTURE; DRUG TARGETING; ENZYME ASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; IN VITRO STUDY; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SIDE EFFECT;

CLINICAL TRIALS; ENZYME INHIBITORS; FMS-LIKE TYROSINE KINASE 3; HUMANS; LEUKEMIA; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 1842430924     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612043452604     Document Type: Review

References (114)

1. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature 2001; 411: 355-365.
2. Alexander WS, Nicola NA. Hemopoietic growth factor receptor abnormalities in leukemia. Leuk Res 1998; 22: 1097-1111.
3. Reilly JT. Class III receptor tyrosine kinases: Role in leukaemogenesis. Br J Haematol 2002; 116: 744-757.
4. Gilliland DG, Griffin JD. The roles of FLT3 in hematopoiesis and leukemia. Blood 2002; 100: 1532-1542.
5. Levis M, Small D. FLT3:ITDoes matter in leukemia. Leukemia 2003; 17: 1750-1760.
6. Lowenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med 1999; 341: 1051-1062.
7. Tse KF, Novelli E, Civin CI, Bohmer FD, Small D. Inhibition of FLT3-mediated transformation by use of a tyrosine kinase inhibitor. Leukemia 2001 15: 1001-1010.
8. Levis M; Tse KF, Smith BD, Garrett E, Small D. A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations. Blood 2001; 98: 885-887.
9. Levis M, Allebach J, Tse KF, Zheng R, Baldwin BR, Smith BD, et al. A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. Blood 2002; 99: 3885-3891.
10. Kelly LM, Yu JC, Boulton CL, Apatira M, Li J, Sullivan CM, et al. CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML). Cancer Cell 2002; 1: 421-432.
11. Weisberg E, Boulton C, Kelly LM, Manley P, Fabbro D, Meyer T, et al. Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell 2002; 1: 433-443.
12. Teller S, Kramer D, Bohmer SA, Tse KF, Small D, Mahboobi S, et al. Bis(1H-2-indolyl)-1-methanones as inhibitors of the hematopoietic tyrosine kinase Flt3. Leukemia 2002; 16: 1528-1534.
13. O'Farrell AM, Abrams TJ, Yuen HA, Ngai TJ, Louie SG, Yee KW, et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 2003; 101: 3597-3605.
14. Yee KW, O'Farrell AM, Smolich BD, Cherrington JM, McMahon G, Wait CL, et al. SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase. Blood 2002; 100: 2941-2949.
15. Gazit A, Yee K, Uecker A, Bohmer FD, Sjoblom T, Ostman A, et al. Tricyclic quinoxalines as potent kinase inhibitors of PDGFR kinase, Flt3 and Kit. Bioorg Med Chem 2003; 11: 2007-2018.
16. Murata K, Kumagai H, Kawashima T, Tamatsu K, Irie M, Nakajima H, et al. Selective cytotoxic mechanism of GTP-14564, a novel tyrosine kinase inhibitor in leukemia cells expressing a constitutively active FLT3 8. J Biol Chem (Epub) 2003.
17. Rosnet O, Schiff C, Pebusque MJ, Marchetto S, Tonnelle C, Toiron Y, et al. Human FLT3/FLK2 gene: CDNA cloning and expression in hematopoietic cells. Blood 1993; 82: 1110-1119.
18. Small D, Levenstein M, Kim E, Carow C, Amin S, Rockwell P, et al. STK-1, the human homolog of Flk-2/Flt-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor/stem cells. Proc Natl Acad Sci USA 1994; 91: 459-463.
19. van der Geer P, Hunter T, Lindberg RA. Receptor protein-tyrosine kinases and their signal transduction pathways. Annu Rev Cell Biol 1994; 10: 251-337.
20. Dosil M, Wang S, Lemischka IR. Mitogenic signalling and substrate specificity of the Flk2/Flt3 receptor tyrosine kinase in fibroblasts and interleukin 3-dependent hematopoietic cells. Mol Cell Biol 1993; 13: 6572-6585.
21. Rosnet O, Buhring HJ, deLapeyriere O, Beslu N, Lavagna C, Marchetto S, et al. Expression and signal transduction of the FLT3 tyrosine kinase receptor. Acta Haematol 1996; 95: 218-223.
22. Lavagna-Sevenier C, Marchetto S, Birnbaum D, Rosnet O, FLT3 signaling in hematopoietic cells involves CBL, SHC and an unknown P115 as prominent tyrosine-phosphorylated substrates. Leukemia 1998; 12: 301-310.
23. Lavagna-Sevenier C, Marchetto S, Birnbaum D, Rosnet O. The CBL-related protein CBLB participates in FLT3 and interleukin-7 receptor signal transduction in pro-B cells. J Biol Chem 1998; 273: 14962-14967.
24. Zhang S, Mantel C, Broxmeyer HE. Flt3 signaling involves tyrosylphosphorylation of SHP-2 and SHIP and their association with Grb2 and Shc in Baf3/Flt3 cells. J Leukoc Biol 1999; 65: 372-380.
25. Marchetto S, Fournier E, Beslu N, Aurran-Schleinitz T, Dubreuil P, Borg JP, et al. SHC and SHIP phosphorylation and interaction in response to activation of the FLT3 receptor. Leukemia 1999; 13: 1374-1382.
26. Zhang S, Fukuda S, Lee Y, Hangoc G, Cooper S, Spolski R, et al. Essential role of signal transducer and activator of transcription (Stat)5a but not Stat5b for Flt3-dependent signaling. J Exp Med 2000; 192: 719-728.
27. Hannum C, Culpepper J, Campbell D, McClanahan T, Zurawski S, Bazan JF, et al. Ligand for FLT3/FLK2 receptor tyrosine kinase. regulates growth of haematopoietic stem cells and is encoded by variant RNAs. Nature 1994; 368: 643-648.
28. Lyman SD, James L, Johnson L, Brasel K, de Vries P, Escobar SS, et al. Cloning of the human homologue of the murine flt3 ligand: A growth factor for early hematopoietic progenitor cells. Blood 1994; 83: 2795-2801.
29. Lyman SD, Jacobsen SE. c-kit ligand and Flt3 ligand: stem/progenitor cell factors with overlapping yet distinct activities. Blood 1998; 91: 1101-1134.
30. Gotze KS, Ramirez M, Tabor, Small D, Matthews W, Civin CI. Flt3high and Flt3low CD34+ progenitor cells isolated from human bone marrow are functionally distinct. Blood 1998; 91: 1947-1958.
31. Mackarehtschian K, Hardin JD, Moore KA, Boast S, Goff SP, Lemischka IR. Targeted disruption of the flk2/flt3 gene leads to deficiencies in primitive hematopoietic progenitors. Immunity 1995; 3: 147-161.
32. McKenna HJ, Stocking KL, Miller RE, Brasel K, De Smedt T, Maraskovsky E, et al. Mice lacking flt3 ligand have deficient hematopoiesis affecting hematopoietic progenitor cells, dendritic cells, natural killer cells. Blood 2000; 95: 3489-3497.
33. Ray RJ, Paige CJ, Furlonger C, Lyman SD, Rottapel R. Flt3 ligand supports the differentiation of early B cell progenitors in the presence of interleukin-11 and interleukin-7. Eur J Immunol 1996, 26: 1504-1510.
34. Veiby OP, Jacobsen FW, Cui L, Lyman SD, Jacobsen SE. The flt3 ligand promotes the survival of primitive hemopoietic progenitor cells with myeloid as well as B lymphoid potential. Suppression of apoptosis and counteraction by TNF-alpha and TGF-beta. J Immunol 1996; 157: 2953-2960.
35. Broxmeyer HE, Lu L, Cooper S, Ruggieri L, Li ZH, Lyman SD. Flt3 ligand stimulates/costimulates the growth of myeloid stem/progenitor cells. Exp Hematol 1995; 23: 1121-1129.
36. Hirayama F, Lyman SD, Clark SC, Ogawa M. The flt3 ligand supports proliferation of lymphohematopoietic progenitors and early B-lymphoid progenitors. Blood 1995; 85: 1762-1768.
37. Nicholls SE, Winter S, Mottram R, Miyan JA, Whetton AD. Flt3 ligand can promote survival and macrophage development without proliferation in myeloid progenitor cells. Exp Hematol 1999; 27: 663-672.
38. Sitnicka E, Buza-Vidas N, Larsson S, Nygren JM, Liuba K, Jacobsen SE. Human CD34+ hematopoietic stem cells capable of multilineage engrafting NOD/SCID mice express flt3: Distinct flt3 and c-kit expression and response patterns on mouse and candidate human hematopoietic stem cells. Blood 2003; 102: 881-886.
39. Meierhoff G, Dehmel U, Gruss HJ, Rosnet O, Birnbaum D, Quentmeier H, et al. Expression of FLT3 receptor and FLT3-ligand in human leukemia-lymphoma cell lines. Leukemia 1995; 9: 1368-1372.
40. Drexler HG. Expression of FLT3 receptor and response to FLT3 ligand by leukemic cells. Leukemia 1996; 10: 588-599.
41. Carow CE, Levenstein M, Kaufmann SH, Chen J, Amin S, Rockwell P, et al. Expression of the hematopoietic growth factor receptor FLT3 (STK-1/Flk2) in human leukemias. Blood 1996; 87: 1089-1096.
42. Birg F, Courcoul M, Rosnet O, Bardin F, Pebusque MJ, Marchetto S, et al. Expression of the FMS/KIT-like gene FLT3 in human acute leukemias of the myeloid and lymphoid lineages. Blood 1992; 80: 2584-2593.
43. Rosnet O, Buhring HJ, Marchetto S, Rappold I, Lavagna C, Sainty D, et al. Human FLT3/FLK2 receptor tyrosine kinase is expressed at the surface of normal and malignant hematopoietic cells. Leukemia 1996; 10: 238-248.
44. Nakao M, Yokota S, Iwai T, Kaneko H, Horiike S, Kashima K, et al. Internal tandem duplication of the Flt3 gene found in acute myeloid leukemia. Leukemia 1996; 10: 1911-1918.
45. Yamamoto Y, Kiyoi H, Nakano Y, Suzuki R, Kodera Y, Miyawaki S, et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 2001: 97: 2434-2439.
46. Abu-Duhier FM, Goodeve AC, Wilson GA, Care RS, Peake IR, Reilly JT. Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia. Br J Haematol 2001; 113: 983-988.
47. Kiyoi H, Towatari M, Yokota S, Hamaguchi M, Ohno R, Saito H, et al. Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product. Leukemia 1998; 12: 1333-1337.
48. Kiyoi H, Ohno R, Ueda R, Saito H, Naoe T. Mechanism of constitutive activation of FLF3 with internal tandem duplication in the juxtamembrane domain. Cincogene 2002; 21: 2555-2563.
49. Wybenga-Groot LE, Baskin B, Ong SH, Tong J, Pawson T, Sicheri F. Structural basis for autoinhibition of the Ephb2 receptor tyrosine kinase by the unphosphorylated juxtamembrane region. Cell 2001; 106: 745-757.
50. Huse M, Muir TW, Xu L, Chen YG, Kuriyan J, Massague J. The TGF beta receptor activation process: An inhibitor- to substrate-binding switch. Mot Cell 2001; 8: 671-682.
51. Hubbard SR, Mohammadi M, Schlessinger J. Autoregulatory mechanisms in protein-tyrosine kinases. J Biol Chem 1998; 273: 11987-11990.
52. Nagata H, Worobec AS, Oh CK, Chowdhury BA, Tannenbaum S, Suzuki Y, et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci USA 1995; 92: 10560-10564.
53. Till JH, Ablooglu AJ, Frankel M. Bishop SM, Kohanski RA, Hubbard SR. Crystallographic and solution studies of an activation loop mutant of the insulin receptor tyrosine kinase: Insights into kinase mechanism. J Biol Chem 2001; 276: 10049-10055.
54. Jeffers M, Schmidt L, Nakaigawa N, Webb CP, Weirich G, Kishida T, et al. Activating mutations for the met tyrosine kinase receptor in human cancer. Proc Natl Acad Sci USA 1997; 94: 11445-11450.
55. Kiyoi H, Naoe T, Nakano Y, Yokota S, Minami S, Miyawaki S, et al. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood 1999; 93: 3074-3080.
56. Rombouts WJ, Blokland I, Lowenberg B, Ploemacher RE. Biological characteristics and prognosis of adult acute myeloid leukemia with internal tandem duplications in the Flt3 gene. Leukemia 2000; 14: 675-683.
57. Abu-Duhier FM, Goodeve AC, Wilson GA, Gari MA, Peake IR, Rees DC, et al. FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group. Br J Haematol 2000; 111: 190-195.
58. Stirewalt DL, Kopecky KJ, Meshinchi S, Appelbaum FR, Slovak ML, Willman CL, et al. FLT3, RAS, TP53 mutations in elderly patients with acute myeloid leukemia. Blood 2001; 97: 3589-3595.
59. Kottaridis PD, Gale RE, Frew ME, Harrison G, Langabeer SE, Belton AA, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the First cycle of chemotherapy: Analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 2001; 98: 1752-1759.
60. Whitman SP, Archer KJ, Feng L, Baldus C, Becknell B, Carlson BD, et al. Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: A cancer and leukemia group B study. Cancer Res 2001; 61: 7233-7239.
61. Iwai T, Yokota S, Nakao M, Okamoto T, Taniwaki M, Onodera N, et al. Internal tandem duplication of the FLT3 gene and clinical evaluation in childhood acute myeloid leukemia. The Children's Cancer and Leukemia Study Group, Japan. Leukemia 1999; 13: 38-43.
62. Xu F, Taki T, Yang HW, Hanada R, Hongo T, Ohnishi H, et al. Tandem duplication of the FLT3 gene is found in acute lymphoblastic leukaemia as well as acute myeloid leukaemia but not in myelodysplastic syndrome or juvenile chronic myelogenous leukaemia in children. Br J Haematol 1999; 105: 155-162.
63. Kondo M, Horibe K, Takahashi Y, Matsumoto K, Fukuda M, Inaba J, et al. Prognostic value of internal tandem duplication of the FLT3 gene in childhood acute myelogenous leukemia. Med Pediatr Oncol 1999, 33: 525-529.
64. Meshinchi S, Woods WG, Stirewalt DL, Sweetser DA, Buckley JD, Tjoa TK, et al. Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia. Blood 2001; 97: 89-94.
65. Thiede C, Steudel C, Mohr B, Schaich M, Schakel U, Platzbecker U, et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: Association with FAB subtypes and identification of subgroups with poor prognosis. Blood 2002; 99: 4326-4335.
66. Schnittger S, Schoch C, Dugas M, Kern W, Staib P, Wuchter C, et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: Correlation to cytogenetics, FAB subtype, prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 2002; 100: 59-66.
67. Boissel N, Cayuela JM, Preudhomme C, Thomas X, Grardel N, Fund X, et al. Prognostic significance of FLT3 internal tandem repeat in patients with de novo acute myeloid leukemia treated with reinforced courses of chemotherapy. Leukemia 2002; 16: 1699-1704.
68. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001; 344: 1038-1042.
69. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031-1037.
70. Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIPIL1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003; 348: 1201-1214.
71. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347: 472-480.
72. Palacios R, Steinmetz M. II-3-dependent mouse clones that express B-220 surface antigen, contain Ig genes in germ-line configuration, generate B lymphocytes in vivo. Cell 1985; 41: 727-734.
73. Lange B, Valtieri M, Santoli D, Caracciolo D, Mavilio F, Gemperlein I, et al. Growth factor requirements of childhood acute leukemia: Establishment of GM-CSF-dependent cell lines. Blood 1987; 70: 192-199.
74. Matsuo Y, MacLeod RA, Uphoff CC, Drexler HG, Nishizaki C, Katayama Y, et al. Two acute monocytic leukemia (AML-M5a) cell lines (MOLM-13 and MOLM-14) with interclonal phenotypic heterogeneity showing MLL-AF9 fusion resulting from an occult chromosome insertion, ins(11;9)(q23;p22p23). Leukemia 1997; 11: 1469-1477.
75. Mosmann T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65: 55-63.
76. Ormerod MG. The study of apoptotic cells by flow cytometry. Leukemia 1998; 12: 1013-1025.
77. Tse KF, Allebach J, Levis M, Smith BD, Bohmer FD, Small D. Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitor. Leukemia 2002; 16: 2027-2036.
78. Armstrong SA, Kung AL, Mabon ME, Silverman LB, Stam RW, Den Boer ML, et al. Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. Cancer Cell 2003; 3: 173-183.
79. Lamers MB, Antson AA, Hubbard RE, Scott RK, Williams DH. Structure of the protein tyrosine kinase domain of C-terminal Src kinase (CSK) in complex with staurosporine. J Mol Biol 1999; 285: 713-725.
80. Bohmer FD, Karagyozov L, Uecker A, Serve H, Botzki A, Mahboobi S, et al. A single amino acid exchange inverts susceptibility of related receptor tyrosine kinases for the ATP site inhibitor STI-571. J Biol Chem 2003; 278: 5148-5155.
81. Nagar B, Bornmann WG, Pellicena P, Schindler T, Veach DR, Miller WT, et al. Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res 2002; 62: 4236-4243.
82. Grundler R, Thiede C, Miething C, Steudel C, Peschel C, Duyster J. Sensitivity toward tyrosine kinase inhibitors varies between different activating mutations of the FLT3 receptor. Blood 2003: 102: 646-651.
83. Kovalenko M, Gazit A, Bohmer A, Rorsman C, Ronnstrand L, Heldin CH, et al. Selective platelet-derived growth factor receptor kinase blockers reverse sis-transformation. Cancer Res 1994; 54: 6106-6114.
84. Gazit A, App H, McMahon G, Chen J, Levitzki A, Bohmer FD. Tyrphostins. 5. Potent inhibitors of platelet-derived growth factor receptor tyrosine kinase: Structure-activity relationships in quinoxalines, quinolines, indole tyrphostins. J Med Chem 1996; 39: 2170-2177.
85. Ueda S, Ikeda H, Mizuki M, Ishiko J, Matsumura I, Tanaka H, et al. Constitutive activation of c-kit by the juxtamembrane but not the catalytic domain mutations is inhibited selectively by tyrosine kinase inhibitors STI571 and AG1296. Int J Hematol 2002; 76: 427-435.
86. Griffin JH, Leung J, Bruner RJ, Caligiuri MA, Briesewitz R. Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome. Proc Natl Acad Sci USA 2003; 100: 7830-7835.
87. Mahboobi S, Teller S, Pongratz H, Hufsky H, Sellmer A, Botzki A, et al. Bis(1H-2-indolyl)methanones as a novel class of inhibitors of the platelet-derived growth factor receptor kinase. J Med Chem 2002; 45: 1002-1018.
88. Fong TA, Shawver LK, Sun L, Tang C, App H, Powell TJ, et al. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, growth of multiple tumor types. Cancer Res 1999; 59: 99-106.
89. Mendel DB, Laird AD, Smolich BD, Blake RA, Liang C, Hannah AL, et al. Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an antiangiogenesis agent. Anticancer Drug Des 2000; 15: 29-41.
90. Smolich BD, Yuen HA, West KA, Giles FJ, Albitar M, Cherrington JM. The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts. Blood 2001; 97: 1413-1421.
91. Giles FJ, Cooper MA, Silverman L, Karp JE, Lancet JE, Zangari M, et al. Phase II study of SU5416--a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor--in patients with refractory myeloproliferative diseases. Cancer 2003; 97: 1920-1928.
92. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 2003; 9: 327-337.
93. Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM. SUI1248 Inhibits KIT and Platelet-derived Growth Factor Receptor beta in Preclinical Models of Human Small Cell Lung Cancer. Mol Cancer Ther 2003; 2; 471-478.
94. Whitman SP, Guimond M, Blaser B, Klisovic M, Vukosavlejevic T, Bruner RJ, et al. Primary acute myeloid leukemia (AML) cells with the FLT3 internal tandem duplication (ITD) and absence of wild type (WT) FLT3 (FLT3ITD/- genotype) are distinct from AML with either FLT3wt/wtor FLT3ITD/wt genotypes. Blood 2002; 100: 89a.
95. Ruegg UT, Burgess GM. Staurosporine, K-252 and UCN-01: Potent but nonspecific inhibitors of protein kinases. Trends Pharmacol Sci 1989; 10: 218-220.
96. Yamada K, Iwahashi K, Kase H. K252a, a new inhibitor of protein kinase C, concomitantly inhibits 40K protein phosphorylation and serotonin secretion in a phorbol ester-stimulated platelets. Biochem Biophys Res Commun 1987; 144:, 35-40.
97. Nakanishi S, Matsuda Y, Iwahashi K, Kase H. K-252b, c and d, potent inhibitors of protein kinase C from microbial origin. J Antibiot (Tokyo) 1986; 39: 1066-1071.
98. Nakano H, Kobayashi E, Takahashi I, Tamaoki T, Kuzuu Y, Iba H. Staurosporine inhibits tyrosine-specific protein kinase activity of Rous sarcoma virus transforming protein p60. J Antibiot (Tokyo) 1987; 40: 706-708.
99. George DJ, Dionne CA, Jani J, Angeles T, Murakata C, Lamb J, et al. Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555). Cancer Res 1999; 59: 2395-2401.
100. Fabbro D, Buchdunger E, Wood J, Mestan J, Hofmann F, Ferrari S, et al. Inhibitors of protein kinases: CGP 41251, a protein kinase inhibitor with potential as an anticancer agent. Pharmacol Ther 1999; 82: 293-301.
101. Kelly LM, Liu Q, Kutok JL, Williams IR, Boulton CL, Gilliland DG. FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model. Blood 2002; 99: 310-318.
102. Pandey A, Volkots DL, Seroogy JM, Rose JW, Yu JC, Lambing JL, et al. Identification of orally active, potent, selective 4-piperazinylquinazolines as antagonists of the platelet-derived growth factor receptor tyrosine kinase family. J Med Chem 2002; 45: 3772-3793.
103. Yu JC, Lokker NA, Hollenbach S, Apatira M, Li J, Betz A, et al. Efficacy of the novel selective platelet-derived growth factor receptor antagonist CT52923 on cellular prolilleration, migration, suppression of neointima following vascular injury. J Pharmacol Exp Ther 2001; 298: 1172-1178.
104. Fiedler W, Mesters R, Tinnefeld H, Loges S, Staib P, Duhrsen U, et al. A phase II clinical study of SU5416 in patients with refractory acute myeloid leukemia. Blood. 2003;
105. Smith BD, Levis M, Beran M, Giles F, Kantarjian H, Berg K, et al. Single agent CEP-701, a novel FLT-3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood 2004; [Epub ahead of print].
106. Stone R, Klimeck V, DeAngelo DJ, Nimer S, Estey E, Galinsky I, et al. PKC412, an oral FLT3 inhibitor, has activity in mutant FLT3 acute myeloid leukemia (AML): A phase II clinical trial. Blood 2002; 100: 86a.
107. Heinrich MC, Druker B, Curtin P, Paquette R, Sawyers C, CeAngeloSD, et al. A "fIrst in man" study of the safety and PK/PD of all oral FLT3 inhibitor (MLN518) in patients with AML or high risk myelodysplasia. Blood 2002; 100: 336a.
108. Foran J, Paquette R, Cooper MA, Jacobs M, O'Farrell AM, Kim H, et al. A phase I study of repeated oral dosing with SU11248 for the treatment of patients with acute myeloid leukemia who have failed, or are not eligible for, conventional chemotherapy. Blood 2002; 100: 558a.
109. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293: 876-880.
110. Schindler T, Bornmann W, Pellicena P, Miller WT, Clarkson B, Kuriyan J. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 2000; 289: 1938-1942.
111. Hochhaus A, Kreil S, Corbin AS, La Rosee P, Muller MC, Lahaye T, et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002; 16: 2190-2196.
112. Crump M. Inhibition of raf kinase in the treatment of acute myeloid leukemia. Curr Pharm Design 2002; 8(25): 2243-8.
113. Metcalf CA 3rd, van Schravendijk MR, Dalgarno DC, Sawyer TK. Targeting protein kinases for bone disease: Discovery and development of Src inhibitors. Curr Pharm Design 2002; 8(23): 2049-75.
114. Woolfrey JR, Weston GS. The use of computational methods in the discovery and design of kinase inhibitors. Curr Pharm Design 2002; 8(17): 1527-45.